GRI Bio (NASDAQ
133
0 Kommentare
GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on Autoimmunity
Company reiterates 2024 as year of data
Click here to watch the “What This Means” segment
LA JOLLA, CA, May 22, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the release of a Virtual Investor “What This Means” segment.
Watch the “What This Means” video here
As part of this “What This Means” segment, Marc Hertz, PhD, Chief Executive Officer, Albert Agro, PhD, Chief Medical Officer and Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio discuss the encouraging preclinical data that was recently presented and what this means for its IPF program, GRI-0621, and SLE development programs, GRI-0803 and GRI-0124. Additionally, the Company reiterated its expected upcoming milestones and 2024 as a year of data.
Expected GRI-0621 Upcoming Milestones
- Q3 2024: Report interim data from Phase 2a biomarker study
- Q4 2024: Report topline results from Phase 2a biomarker study
Lesen Sie auch
Expected GRI-0803 Upcoming Milestones
- Q3 2024: Complete IND-enabling studies
- Q3 2024: File IND and launch Phase 1a/b
- Q4 2024: Report Phase 1a single ascending dose (SAD) study topline results
- Q4 2024: Report Phase 1b multiple ascending dose (MAD) study topline results
The Virtual Investor "What This Means" segment featuring GRI Bio is now available here. Additional videos from the "What This Means" series are available on demand at www.virtualinvestorco.com.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.